Skip to content
eventVerified

NIH–Moderna Phase 1 trial of COVID-19 mRNA vaccine mRNA-1273 began dosing

Dated 16 March 2020: NIH–Moderna Phase 1 trial of COVID-19 mRNA vaccine mRNA-1273 began dosing. In the causal graph this event strengthens the driver mRNA-Platform Development.

Who was responsible

Contribution type and responsibility level for each recorded actor — not sole-author shorthand.

No public contributors are listed for this fact.

What changed

Fact → Driver → Indicator. Relationship strength orders the paths; it is not the observed indicator movement.

    1. FactNIH–Moderna Phase 1 trial of COVID-19 mRNA vaccine mRNA-1273 began dosing
    2. strengthensDrivermRNA-Platform Development

    provisional weight · verified

Causal path

How this event connects to drivers and indicators in the graph.

  1. FactNIH–Moderna Phase 1 trial of COVID-19 mRNA vaccine mRNA-1273 began dosing
  2. strengthensDrivermRNA-Platform Development

Cite this page

Factrail. (2026). NIH–Moderna Phase 1 trial of COVID-19 mRNA vaccine mRNA-1273 began dosing. Factrail. https://factrail.ai/facts/moderna-mrna-1273-nih-phase1-first-dose-2020

https://factrail.ai/facts/moderna-mrna-1273-nih-phase1-first-dose-2020

Accessed 15 October 2026.

By the Factrail desk · Method: how we source and score · Last reviewed

Dispute this factNamed here, or represent someone who is? Request a right of reply.